REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.70
Bid: 3.66
Ask: 3.70
Change: -0.10 (-2.63%)
Spread: 0.04 (1.093%)
Open: 3.70
High: 3.70
Low: 3.70
Prev. Close: 3.80
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on sugarcane in Brazil

30 Jul 2018 07:00

RNS Number : 0790W
Plant Health Care PLC
30 July 2018
 

 

 

30 July 2018

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

 

Update on sugarcane in Brazil

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, provides the following update on Harpin αβ launch in Brazil.

 

 

Highlights

- Harpin αβ applied in sugarcane in Brazil; demonstration plot yield increase of 20% or more.

- Harpin αβ was launched in Brazil sugarcane in February 2018 through Coplacana under the brand name H2Copla. Grower feedback has been strong.

- Since the launch of H2Copla in February 2018, the product has generated revenue of $400k. The Company expects to generate at least as much revenue from H2Copla in the second half of 2018.

- The Company is now planning for the launch of Harpin αβ in coffee, which has similar potential to sugarcane.

 

With 10 million hectares planted, Brazil sugarcane is an important target for Plant Health Care. The Company has been developing Harpin αβ for use in this crop. Trials have been conducted in both ratoon cane (i.e. cane which grows back after harvest) and newly planted cane (normal practice is to take five crops from ratton cane, then plant again). Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha) at six to eight weeks after harvest, significantly increased the yield of ratoon cane (10-29%) in ratoon cane. Moreover, it is possible that the ratoon crop may be extended from five to six years, which is a material cost reduction, especially when sugar prices are low. Trials also indicated that newly planted cane responds well to applications of Harpin αβ.

 

Based on these promising results, as announced on 16 July 2018, the Company launched a Harpin αβ product with Coplacana, a leading sugarcane co-operative in Brazil, for their exclusive use of the H2Copla brand in sugarcane. Coplacana services more than 70% of the sugarcane hectares in Sao Paolo state, where more than 5 million hectares of the crop are grown. Demonstration trials with Coplacana have shown impressive results, with an average yield increase of over 20%.

 

H2Copla was launched in February 2018 and the product has received very positive grower feedback. The launch quantities have been largely sold and the Company expects to make further sales during the second half of 2018. We confidently expect sales in Brazilian sugarcane to build in the second half of 2018 and over the coming years.

 

Arnaldo Bortoletto, President of Coplacana, said "We continue to have excellent field results with H2Copla, with good grower feedback and we expect strong demand for H2Copla in the second half of 2018".

 

Jeff Tweedy, Commercial Head, Americas for Plant Health Care, said: "We are very encouraged by the support we are receiving from Coplacana in promoting H2Copla in the field and have high expectations for future sales. The Company is now developing Harpin αβ in other crops. In 2017/18, we had most encouraging preliminary results in coffee, with both yield and quality improvements. We are now examining routes to market for Harpin αβ in this crop, with a view to launching for the 2019-2020 growing season. We see coffee as being at least as valuable a crop for the Company as sugarcane."

 

 

 

For further information, please contact:

 

Plant Health Care plc

Chris Richards, Executive Chairman and Interim CEO Tel: +1 919 926 1600

Jeffrey Tweedy, Commercial Head, Americas

 

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke Tel: +44 (0) 20 3100 2000

 

Arden Partners plc - Joint BrokerJohn Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

 

IFC Advisory - Financial PR

Graham Herring / Miles Nolan / Zach Cohen Tel: +44 (0) 20 3934 6633

 

 

Company website: www.planthealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBIGDRCSDBGIR
Date   Source Headline
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.